Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, offers been shown to boost the survival price of individuals with advanced HER2-positive breasts cancers. individually of HDAC inhibition. However, TSA decreased EGFR 3UTR activity and induced the gene manifestation of microRNA-7, a known EGFR-targeting microRNA. Furthermore, treatment with microRNA-7 inhibitor attenuated TSA-mediated EGFR suppression. These outcomes claim… Continue reading Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, offers been shown to